Ondine Biomedical launches £5m share issue to fund NDA push and extend cash runway

Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.

Ondine Biomedical plans to raise about £5 million through a non‑underwritten placing and subscription of new common shares at 12 pence, with directors and certain employees participating, and an additional c.£0.3 million to be raised from selected investors under regulatory exemptions. The net proceeds are earmarked to fund New Drug Application preparation, large‑scale GMP production and stability work, commercial and operational support, and to extend the company’s cash runway into early Q4 2026.

The company has completed patient enrolment in its pivotal LANTERN Phase 3 study, with top‑line results expected in spring 2026, and is targeting a pre‑NDA meeting with the FDA in early Q4 2026. Alongside these clinical and regulatory milestones, Ondine reported an unaudited 29% revenue increase for 2025 on the back of new hospital deployments and higher utilisation, and it continues measured commercial expansion in Canada and internationally while planning to release full‑year 2025 results in early June 2026.

Spark’s Take on OBI Stock

According to Spark, TipRanks’ AI Analyst, OBI is a Underperform.

Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.

To see Spark’s full report on OBI stock, click here.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company listed on AIM that develops antimicrobial technologies for use in hospitals. Its commercial focus is on deploying its products into healthcare facilities, particularly in North America and internationally, using a ‘land and expand’ strategy driven by clinical and real‑world evidence.

Average Trading Volume: 269,723

Technical Sentiment Signal: Buy

Current Market Cap: £64.8M

Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.